trending Market Intelligence /marketintelligence/en/news-insights/trending/v2-kgRrJ8HO3k1ijZ_MFgA2 content esgSubNav
In This List

LBT Innovations laboratory instrument gets US FDA clearance

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


LBT Innovations laboratory instrument gets US FDA clearance

Australia's LBT Innovations Ltd. said its APAS Independence instrument received the U.S. Food and Drug Administration's 510(k) clearance.

The APAS Independence instrument with associated urine analysis module allows the automatic reading of culture plates, streamlining the plate triaging stage in the microbiology workflow.

The commercial instrument, classified as a class II medical device, was developed by Clever Culture Systems, LBT Innovations' 50%-owned joint venture unit.

Adelaide, South Australia-based LBT Innovations is engaged in the research and development of technologies for the healthcare and laboratory supply markets in Australia, Switzerland and the U.S.